CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Enveda, an AI drugmaker, banks $311M in venture funding

Positive
AI Analysis

Summary

Enveda secured $311M in venture funding to advance its AI-powered drug discovery platform that identifies candidates from plants and microbes. The company has three candidates in human testing for immune diseases and obesity.

Importance:6/10
Sentiment:
0.70
venture fundingAI drug discoveryclinical stageimmune diseasesobesity

Read the original article

Published by BioPharma Dive on September 23, 2026 5:55 PM

Read Original